耳蜗蜗轴剂量对非前庭神经鞘瘤侧颅底肿瘤立体定向放疗后听力保留的影响
该回顾性队列研究纳入16例侧颅底非前庭神经鞘瘤(脑膜瘤或颈静脉副神经节瘤)及43例散发性前庭神经鞘瘤患者,均接受立体定向放射外科治疗且蜗轴剂量>5 Gy。非前庭神经鞘瘤患者可服务听力保留率为81%,前庭神经鞘瘤为56%(p=0.07)。结论认为5 Gy蜗轴剂量阈值不能预测非前庭神经鞘瘤患者的听力损失。
要点
- 蜗轴剂量>5 Gy不预测非前庭神经鞘瘤患者放疗后听力损失。
- 非前庭神经鞘瘤听力保留率81%,前庭神经鞘瘤56%,差异无统计学意义。
- 非前庭神经鞘瘤中听力损失均见于小脑脑桥角脑膜瘤。
核心结论
- 蜗轴剂量5 Gy阈值不能预测非前庭神经鞘瘤侧颅底肿瘤立体定向放射外科后的听力损失。
- 源自前庭神经鞘瘤的剂量学参数可能不适用于非前庭神经鞘瘤人群。
研究设计与样本
- 回顾性队列研究,纳入2007-2016年接受立体定向放射外科治疗、治疗前可服务听力且蜗轴剂量>5 Gy的侧颅底脑膜瘤或颈静脉副神经节瘤患者16例。
- 对照组为连续筛选的散发性前庭神经鞘瘤患者43例。
主要发现
- 非前庭神经鞘瘤患者可服务听力(AAO-HNS A/B级)保留13例(81%),前庭神经鞘瘤保留23例(56%),p=0.07。
- 非前庭神经鞘瘤中3例听力损失均发生于小脑脑桥角脑膜瘤。
- 听力保留的非前庭神经鞘瘤患者蜗轴中位剂量6.9 Gy(范围5.7-19.2 Gy),听力损失者7.4 Gy(范围5.4-7.6 Gy),p=0.53。
- 散发性前庭神经鞘瘤患者蜗轴点剂量中位6.8 Gy(范围5.4-11.7 Gy)。
临床怎么用
- 对非前庭神经鞘瘤侧颅底肿瘤行立体定向放射外科时,不应直接套用前庭神经鞘瘤的蜗轴剂量5 Gy阈值预测听力风险。
- 不同病理类型听力损失风险可能不同,副神经节瘤和岩斜脑膜瘤风险低于直接压迫耳蜗神经的小脑脑桥角脑膜瘤。
局限性
- 样本量小(非前庭神经鞘瘤16例,前庭神经鞘瘤43例),统计效能有限。
- 为回顾性队列研究,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Radiation dose to the cochlea has been proposed as a key prognostic factor in hearing preservation following stereotactic radiosurgery (SRS) for vestibular schwannoma (VS). However, understanding of the predictive value of cochlear dose on hearing outcomes following SRS for patients with non-VS tumors of the lateral skull base (LSB) is incomplete. The authors investigated rates of hearing loss following high-dose SRS in patients with LSB non-VS lesions compared with patients with VS. METHODS: Patients with LSB meningioma or jugular paraganglioma and serviceable pretreatment hearing who underwent SRS treatment during 2007-2016 and received a modiolus dose > 5 Gy were included in a retrospective cohort study, along with a similarly identified control group of consecutive patients with sporadic VS. RESULTS: Sixteen patients with non-VS tumors and a control group of 43 patients with VS met study criteria. Serviceable hearing, defined as American Academy of Otololaryngology-Head and Neck Surgery class A/B, was maintained in 13 non-VS versus 23 VS patients (81% vs 56%, p = 0.07). All 3 instances of hearing loss in non-VS patients were observed in cerebellopontine angle (CPA) meningiomas. Non-VS with preserved hearing had a median modiolus dose of 6.9 Gy (range 5.7-19.2 Gy), versus 7.4 Gy (range 5.4-7.6 Gy) in those patients with post-SRS hearing loss (p = 0.53). Sporadic VS patients received an overall median modiolus point-dose of 6.8 Gy (range 5.4-11.7 Gy). CONCLUSIONS: The modiolus dose threshold of 5 Gy does not predict hearing loss in patients with non-VS tumors undergoing SRS, suggesting that dosimetric parameters derived from VS may not be applicable to this population. Differential rates of hearing loss appear to vary by pathology, with paragangliomas and petroclival meningiomas demonstrating decreased risk of hearing loss compared to CPA meningiomas that may directly compress the cochlear nerve similarly to VS.
引用
- Carlstrom LP, Jacob JT, Graffeo CS, et al. Impact of cochlear modiolus dose on hearing preservation following stereotactic radiosurgery for non-vestibular schwannoma neoplasms of the lateral skull base: a cohort study. J Neurosurg. 2019. PMID: 31299651. doi:10.3171/2019.4.JNS19201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。